Platelet aggregation, secretion and thrombus formation play a critical role in primary hemostasis to prevent excessive blood loss. On the other hand, uncontrolled platelet activation leads to pathological thrombus formation resulting in myocardial infarction or stroke. Stimulation of heterotrimeric G-proteins by soluble agonists or immunoreceptor tyrosine based activation motif-coupled receptors that interact with immobilized ligands such as the collagen receptor glycoprotein (GP) VI lead to the activation of phospholipases that cleave membrane phospholipids to generate soluble second messengers. Platelets contain the phospholipase (PL) D1 and D2 which catalyze the hydrolysis of phosphatidylcholine to generate the second messenger phosphatidic acid (PA). The production of PA is abrogated by primary alcohols that have been widely used for the analysis of PLD-mediated processes.
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Introduction
Platelets, small anucleated cells produced by bone marrow megakaryocytes, circulate in the blood as sentinels of vascular integrity. At sites of vascular damage they rapidly adhere to the exposed sub-endothelial matrix, aggregate, and form a thrombus to seal the injury; and, as such, play a pivotal role in primary hemostasis to prevent bleeding and blood loss [1;2] .
On the other hand, inappropriate platelet aggregation and thrombus formation may lead to vascular occlusions resulting in myocardial infarction or stroke [3;4] .
Platelet activation induced by a primary agonist, such as collagen or thrombin, leads to the generation and liberation of thromboxane A 2 (TXA 2 ) as well as to the secretion of alpha-and dense granules, the latter embodies the adenine nucleotides ATP and ADP. Once released, these secondary mediators amplify platelet activation via their respective receptors finally leading to the activation of integrin  IIb  3 , which provides the molecular basis for platelets forming fibrinogen-bridged aggregates [4;5] . The subendothelial matrixprotein collagen activates platelets mainly via glycoprotein (GP) VI, which induces via FcR a signaling cascade involving tyrosine kinases such as src and syk as well as phospholipase (PLC) 2 [6] . The serine-protease thrombin triggers the activation of human platelets via proteaseactivated receptors (PARs) 1 and 4. These proteins belong to the family of G protein-coupled receptors (GPCRs) that act via G 12/13 and G q [7;8] . Although PAR-1 and PAR-4 are coupled with the same G-protein subtypes, they appear to exhibit differential affinities for thrombin and durations of intracellular signaling [9] . In contrast mouse platelets express PAR-3 and PAR-4, whereby PAR-3 does not induce intercellular signaling but serves as a co-factor for PAR-4 [8] . Whereas Gα 12/13 signaling accounts for instant cytoskeletal reorganization (platelet "shape change") via calcium/calmodulin and Rho/Rho-kinase signaling [10;11] , Gα q signaling induces PLC isoform β activation [12] . Activated PLC  and 2 cleave phosphatidylinositol 4,5-bisphosphate (PIP 2 ) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ) [13] . IP 3 triggers the release of Ca 2+ from intracellular stores which in concert with DAG activates protein kinase C (PKC), a protein implicated in platelet granule Elvers et al. PLD as negative regulator of platelets 4 secretion [12] [13] [14] . Furthermore, an increase in intracellular Ca 2+ also accounts for activation of phospholipase A2 leading to the release of arachidonic acid which converted to TXA 2 in a cyclooxygenase-dependent manner. For TXA 2 the thromboxane/prostanoid receptor  (TP)
is the predominant isoform in platelets and, like PAR-1 and PAR-4, is coupled with G 12/13 and G q [15;16] . Whereas intermediate TXA 2 signaling supports platelet activation and aggregation specifically at low concentrations of thrombin, dense granule secretion and therefore aggregation in response to high concentrations of collagen markedly relies on TXA 2 synthesis and signaling [17] .
For ADP the G q -coupled P 2 Y 1 receptors and G i2 -coupled P 2 Y 12 receptors have been identified on platelets [18;19] . The /-subunits of G i directly induce phospoinositol-3-kinase (PI3-K) leading to an enhancement of granule secretion and activation of integrin  IIb  3
("inside-out" signaling) whereas the inhibitory -subunit down regulates adenylyl cyclase (AC) and therefore cyclic adenosine monophosphate (cAMP) levels which both are pivotal for full and sustained platelet activation and aggregation [18;19] . Finally, fibrinogen-binding to activated integrin  IIb  3 , besides bridging platelets to form aggregates, also contributes to platelet activation and secretion by "outside-in" signaling [20] .
Platelet activation by all these signaling pathways lead to the activation of phospholipase D, an enzyme, that catalyses the hydrolysis of phosphatidylcholine into phosphatidic acid (PA) and choline [21] . PA, as well as its metabolites lysoPA and diacylglycerol (DAG) are important second messengers [21] . In the presence of a primary alcohol, such as ethanol or 1-butanol, the alcohol is the preferred substrate, resulting in the generation of the respective phosphatidylalcohols which are metabolically stable and can be quantified for assessing PLD activity [21] . Furthermore, as phosphatidylalcohols have been thought to be inert regarding cellular signaling primary alcohols have been widely applied to interfere with proper PLDmediated PA production to investigate the cellular role(s) of PLD [21;22] .
Two isoforms of PLD, PLD1 and PLD2, have been identified. While PLD1 has a low basal activity and is readily activated by PKC and small GTPases of the adenosine diphosphate 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Elvers et al. PLD as negative regulator of platelets 5 marginally induced by a variety of activators. In platelets, both PLD isoforms are present [23] .
PLD has been reported to be activated by collagen, thrombin, and the TXA 2 -mimetic U46619
and, taken together, is thought to be implicated in platelet activation and secretion [24] [25] [26] [27] .
This was further supported by the analysis of Pld1 -/-platelets that identified PLD1 as critical regulator of platelet activity. The lack of PLD1 in platelets induces impaired integrin  IIb  3 activation and shear dependent thrombus formation leading to protection against arterial thrombosis and ischemic brain infarction [28] . However, the absence of specific inhibitors and mice that are deficient in the PLD isoform PLD2 precluded the analysis of PLD2 function in platelets.
Recently the novel pharmacological PLD-inhibitor FIPI has been developed and characterized [22] . Most intriguingly, it was found that cellular responses applying 1-butanol or FIPI essentially differed, strongly suggesting that the proposed role(s) of PLD need(s) to be re-evaluated. In this study we found that FIPI induced PLD inhibition resulted in enhanced PKC-mediated secretion and aggregation in human platelets. As comparable effects of FIPI were found with mouse wild-type and Pld1 -/-platelets our findings strongly point to a new role for PLD2 as negative regulator of platelet sensitivity.
Material and methods

Chemicals and Antibodies
indolyl des-clorohalopemide hydrochloride hydrate), apyrase (Grade III, from potatoe), aspirin (acetylsalicylic acid), fura-2/AM (fura 2 acetoxymethylester), bovine thrombin (T4648), and U46619 (9,11-dideoxy-11, 9 -epoxy-methanoprostaglandine (F2) were purchased from Sigma. Collagen (type I, from equine tendons) and the luciferin/luciferase reagent including the ATP-standard (CHRONOLUME ® ) were from Chrono-Log.ICI192,605 (4-(Z)-6-
were from Tocris.
AYPGKF-NH 2 and SFLLRN were custom-synthesized by JPT Peptide Technologies.
ReoPro (abciximab) was from Eli Lilly, and Cangrelor® was a kind gift from the Medicines
Company.All other reagents were of analytical grade.
The phospho-MLC2 (Ser19) antibody (#3675), the phospho-(Ser) PKC Substrate Antibody (#2261), as well as the HRP-conjugated secondary antibodies (#7074 and #7076) were from Cell Signaling Technology; the antibody detecting unmodified pleckstrin was from Abcam (ab17020), and the -tubulin antibody (clone AA2) from Upstate/Millipore.
Preparation of isolated human platelets
Heparinized blood (10 U/ml) was obtained from Linköping University Hospital"s blood bank.
Blood was transferred in a volumetric proportion of 5:1 to acid-citrate-dextrose (ACD: 71 mM citric acid, 85 mM sodium citrate, 111 mM glucose) and centrifuged at 220 g for 20 min. The platelet-rich plasma (PRP) thus obtained was incubated with 100 µM aspirin for 30 min, and platelets were collected by centrifugation at 520 g for 25 min. 
Human platelet aggregation and ATP release
Measurements were performed at 37°C using a Chronolog Dual Channel lumi-aggregometer (Model 560, Chrono-Log, Haverston, PA, USA) with stirring at 800 rpm using a final volume of 0.3 ml platelet suspension. Aggregation is expressed as percentage light transmission compared to KRG alone (=100%). Extracellular ATP was assessed applying the luciferin/luciferase bioluminescent assay and calculated using an exogenously added ATP standard.
Human platelet Ca 2+ mobilization measurements
Platelets were loaded with fura-2 by incubating PRP with 3 μM fura-2/AM for 45 min at RT and subsequently isolated as described above. Platelets were pre-incubated and stimulated as indicated at 37°C and fluorescence was recorded using a Hitachi F-7000 spectrofluorometer (Hitachi Ltd., Tokyo, Japan) at 510 nm with simultaneous excitation at 340 nm and 380 nm. Cytosolic calcium [Ca 2+ ] i is expressed in fluorescence ratio (340/380 nm).
Immuno(Western)blotting
Stimulation of human platelets were carried out at 37°C in a total volume of 200 μl in 2 ml round-bottom tubes in a thermoshaker rotating at 900 rpm; pre-incubations at 500 rpm.
Reactions were stopped by the addition of 50 μl 5x SDS sample buffer, and proteins were denatured at 95°C for 5 min. Tokyo, Japan).
Animals
Pld mutant mice were described before [69] . Pld +/-mice were intercrossed to generate Pld
and Pld -/-mice. Ablation of PLD1 was monitored by PCR and immunoblotting, as previously described. Animal studies were performed in accordance with the guidelines for the use of living animals in scientific studies and the German law for the protection of animals and approved by the Regional Council Tübingen (Regierungspräsidium Tübingen).
Murine platelet preparation
Mice were bled form the retro-orbital plexus and murine blood was collected in a tube.
Citrate-anticoagulated blood was centrifugated at 1800 rpm for 5 minutes at room temperature. To obtain platelet-rich plasma (PRP) the supernatant was centrifugated at 800 rpm for 6 min. For the preparation of washed platelets PRP was washed twice at 2800 rpm for 5 min at room temperature and the pellet was resuspended in Tyrode"s buffer [136 mM NaCl, 0.4 mM Na 2 HPO 4 , 2.7 mM KCl, 12 mM NaHCO 3 , 0.1 % glucose, 0.35 % bovine serum albumin (BSA), pH 7.4] supplemented with prostacyclin (0.5 μM) and apyrase (0.02 U/mL). Before use, platelets were resuspended in the same buffer without prostacyclin (pH 7.4, 0.02 U/mL apyrase) and incubated at 37 °C for 30 min.
Murine platelet aggregometry and ATP-release measurement
Aggregation experiments were performed with fresh isolated mouse platelets using light transmission aggregometry. Experiments were done with a Chrono Log lumi aggregometer PLD activity was determined for each sample by measuring fluorescence activity after a 1-hour incubation at 37°C in the dark with the GloMax®-Multi detection system (Promega). A standard curve with different concentrations ranging from 0 to 250 mU/ml was performed using purified PLD from Streptomyces chromofuscus (Sigma-Aldrich). 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Elvers et al.
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Statistical analysis
Data analysis was performed using GraphPad Prism 4 software (GraphPad Software Inc., San Diego, CA, USA). Results are presented as mean ± standard error of the mean (S.E.M.)
and statistical significances were calculated as indicated 
Results
PLD is a signaling enzyme that generates the second messenger PA implicated in many cellular processes like adhesion, integrin activation [28] , cell spreading [29] , chemotaxis [22] and Ras activation [30] . PA production by PLD is abrogated by primary alcohol derivates like ethanol or 1-butanol. Furthermore, several other inhibitors of PLD activity have been investigated like ceramide [31] , neomycin [32] and natural products [33] . However, these compounds sequester the essential co-factor of PLD PIP 2 , work indirectly to inhibit PLD or display many other effects on signaling pathways making their use more complicated and the interpretation of data difficult. In order to validate PLD function in human and murine platelets the present study makes use of the analog 5-fluoro-2-indolyl des-chloro-halopemide (FIPI)
that has been shown to potently inhibit PLD1 and PLD2 [22;34] .
PLD inhibition by FIPI enhances platelet dense granule secretion and aggregation in human platelets
FIPI was reported to inhibit both PLD1 and PLD2 in a dose-dependent manner, with 50% loss of activity observed at approximately 25 nM [22] . Thus, FIPI is a potent, concentrationdependent PLD2 inhibitor that inhibits PLD1 equally well under in vitro assay conditions [22;34] . To elucidate the impact of FIPI on platelet function we tested the influence of the inhibitor on human platelet dense granule secretion and aggregation and performed measurements using a Chronolog Dual Channel lumi-aggregometer. Aggregation was expressed as percentage light transmission and extracellular ATP as a marker for dense granule secretion was assessed by a luciferin/luciferase bioluminescent assay. Because 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Fig. 2A ). In line with these results, the increase of cytosolic Ca 2+ activity triggered by different concentrations of the PAR-4 activating peptide was similar in control and FIPI-treated human platelets (Fig. 2C ).
PLD mediated production of PA is inhibited by primary alcohols due to the generation of phosphatidylalcohol. Thus we compared the effect of FIPI and primary alcohols on cellular processes such as Ca 2+ mobilization by performing additional spectrofluorimetric measurements in the presence of ethanol and 1-butanol. As shown in Fig. 2A S2D ).
We have not been able to measure ATP release following 1-butanol treatment with the luciferin/luciferase assay, most likely due to a disruption of the reagent(s); as the signal normally evoked by the externally added ATP standard was almost completely abrogated (data not shown). However, this observation further suggests that 1-butanol causes PLDindependent effects
Taken together, these results provide strong evidence that the FIPI-mediated inhibition of PLD enhances platelet dense granule secretion and aggregation but has no influence on Ca 2+ mobilization, whereas ethanol and 1-butanol display distinct inhibitory effects on ATP release, platelet aggregation and Ca 2+ mobilization depending on the applied stimulus.
Proper ROCK signaling is a prerequisite for FIPI-induced effects on dense granule secretion and aggregation
Platelet adhesion and aggregation induces thrombus formation mediated mainly by the actinbased reorganization of the platelet cytoskeleton accompanied by fibrinogen binding to activated integrin  IIb  3 [20] . Small GTPases of the Rho family, namely RhoA, Cdc42 and Rac1, are key regulators of signaling pathways that regulate the reorganization of the cytoskeleton [35] . Furthermore, they play an important role in platelet secretion and activation of Phospholipase C2 [36;37] . To analyze if FIPI-mediated effects on platelet degranulation and aggregation implies RhoA and its downstream effector Rho-associated coiled-coil forming protein serine/threonine kinase (ROCK) we performed experiments using the ROCK inhibitor Y27632. As shown in figure 3A are crucial for thrombus formation [38;39] . Characteristically, upon platelet activation with the induced the characteristic two waves of secretion and thus platelet aggregation ( Fig. 4A-B ).
In addition, these characteristic two waves of secretion and platelet aggregation were observed in both FIPI-treated and control platelets after stimulation with 1 µM TXA 2 . As shown in figure 4A , the first wave of platelet secretion was observed promptly after addition of 1 µM TXA 2 followed by the second wave of platelet secretion. Pre-treatment of human platelets with FIPI enhanced the first wave of platelet secretion compared to control.
To investigate the influence of FIPI on TXA 2 -induced platelet secretion and aggregation in further detail, we assessed the impact of the ADP-activated G i pathway and integrin  IIb  3 outside-in signaling that were both known to be essential for the second wave of secretion and irreversible platelet aggregation. Using the P 2 Y 12 inhibitor Cangrelor® FIPI treated platelets showed a markedly but not significantly reduced first wave of platelet secretion after stimulation with 1 µM TXA 2 while the second wave of secretion was completely abolished ( fig. 4A ). In contrast, while the first wave of secretion was unaltered, the second wave was similarly abrogated in the presence of the monoclonal antibody ReoPro® that binds to integrin  IIb  3 to inhibit fibrinogen binding and thus platelet aggregation. Consequently, platelet aggregation was strongly reduced in platelets pre-treated with Cangrelor® and FIPI or ReoPro® and FIPI compared to controls and FIPI treated platelets ( fig. 4B ).
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Phosphorylation of the protein kinase C substrate pleckstrin is enhanced upon treatment with the PLD inhibitor FIPI
Protein kinase C is a major regulator of platelet granule secretion, integrin activation, aggregation and spreading [40] . Following agonist-induced platelet activation, PKC induces phosphorylation of its substrate pleckstrin that is translocated to the plasma membrane to exert downstream effects on platelet secretion, aggregation and exocytosis [41] . 
5C-D)
. These data suggest that enhanced platelet secretion upon FIPI treatment of human platelets relies on an increase in PKC activity.
PLD inhibition by FIPI augments dense granule secretion and aggregation in murine wild-type and Pld1 -/-platelets
We next investigated the influence of FIPI and thus PLD inhibition on dense granule secretion and aggregation of mouse platelets. Comparable to the results obtained with human platelets ( fig. 1E-F) , we observed enhanced effects of FIPI on dense granule secretion and aggregation of platelets from wild-type mice stimulated with increasing concentrations of PAR-4 activating peptide ( fig. 6A-B ). S4 ). This data also provides evidence that the remaining PLD activity in Pld1 -/-platelets results from basal activity of the PLD2 isoform and does not represent the assay background. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Elvers et al.
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Discussion
The present study unravels a novel putative role for PLD as an endogenous negative regulator of G  /PKC-mediated dense granule secretion and aggregation and thus for platelet activation. Using the pharmacological PLD-inhibitor FIPI we found enhanced dense granule secretion and aggregation in human and mouse wild-type and Pld1 -/-platelets following stimulation with sub-/threshold concentrations of agonists which induce G 12/13 and G q signaling in platelets. While FIPI has no effect on Ca 2+ mobilization and MLC phosphorylation, the effect of FIPI on aggregation and secretion was supported by proper Rho-kinase signaling. Furthermore, FIPI prominently amplified phosphorylation of the PKC substrate pleckstrin known to be associated with granule secretion.
In former studies, primary alcohols have been used to identify PLD/PA driven cellular processes. The presence of 1-butanol in cell culture medium has been shown to inhibit a variety of cell functions [22;42] . Primary alcohols are preferentially used by PLDs to generate phosphatidyl (Ptd)-alcohol instead of PA, thereby abrogating signal transduction processes mediated by PA. However, despite the commonly used primary alcohols over the last decades to block PLD function, it is not clear to date, whether they fully block PA generation and whether they have other effects on cell morphology or function beyond inhibition of PA generation [43;44] . In the present study we compared effects of the PLD-inhibitor FIPI with primary alcohol derivates. In contrast to FIPI, ethanol and especially 1-butanol displayed distinct inhibitory effects on PAR-1 and PAR-4 activating peptide-induced Ca 2+ mobilization, dense granule secretion and aggregation of human platelets indicating that prior studies that rely on PLD inhibition by primary alcohols must be re-evaluated. In the nineties Coorssen and Haslam proposed that PLD is important for human platelet secretion by using ethanol to block PLD mediated effects on degranulation [45] . In a recent study it was shown that 1-butanol abrogated platelet aggregation by PAR-1 but not PAR-4 activating peptide [46] . In the present study we observed similar effects induced by primary alcohols but obtained completely opposite results when FIPI was used to determine platelet secretion and Different approaches to inhibit PLD activity revealed that PLD is involved in exocytosis [47] .
These finding was supported by studies where PLD was inhibited by FIPI, but a limiting aspect of this inhibitor is the dual effect on both PLD isoforms, PLD1 and PLD2, where e.g. secretion can by facilitated by PLD1 while this effect is opposed by PLD2 [22] . In the present study, Ca 2+ influx from the extracellular compartment was unaffected by FIPI. These results indicate that either PLD inhibition by FIPI has no effect on Ca 2+ mobilization or that both PLD isoforms effect Ca 2+ homeostasis in opposed manner thus concealing isoform-specific effects on Ca 2+ mobilization. Furthermore, MLC phosphorylation was not altered upon treatment with FIPI. In contrast, inhibition of ROCK demonstrated that proper Rho-kinase signaling is important for effects on platelet activation mediated by FIPI. Former studies identified PLD as a mediator of cytoskeleton reorganization and proposed PLD2 as master regulator that controls Rho function in neutrophils and other cells [48;49] . Down-regulation of PLD2 was shown to decrease PA production leading to myosin light chain phosphatase (MLCP) release, dephosphorylation of MLC and thus actomyosin disassembly in chinese hamster ovarian (CHO) cells [29] . In addition, PA regulates PI(4)P 5 kinase, which is required for PIP 2 synthesis known to play an important role in membrane ruffling, vesicle trafficking and stress fibre formation [50] . Moreover, Rho-kinase signaling also implies LIM kinase (LIMK) induced phosphorylation of members of the ADF/cofilin family of actin binding and filament severing proteins that may also involve PLD activity [51] . In a recent study by Han and colleagues it has been shown that Cofilin directly and specifically interacts with PLD1 and upon phosphorylation by LIMK, stimulates PLD1 activity [52] .
In the present study we show that FIPI enhanced dense granule secretion in human platelets in response to sub-/threshold concentrations of thrombin, PAR-1 and PAR-4 activating peptide as well as U46619. A role for PLD in secretion and secretory vesicle formation in different cell types was already described several years before [45;53] . PLD was proposed to be important in ARF-dependent exocytosis [54;55] and secretion of neuroendocrine cells recent study from Qin and colleagues provide evidence that PLD2 mediates aldosterone secretion in adrenal glomerulosa cells while PLD1 overexpression had only little effect on aldosterone secretion [59] . PKC is known as major regulator of platelet activity [40] . PKC activity is essential for granule seretion as shown with PKC inhibitors that prevent granule secretion [60;61] and aggregation [62;63] . Pleckstrin is the major substrate for PKC in platelets and macrophages [64] . Mice lacking pleckstrin display marked defects in exocytosis of granula, integrin activation and aggregation in response to PKC stimulation [41] . Here we
show, that FIPI induced inhibition of PLD led to amplified phosphorylation of pleckstrin indicating that PLD plays a putative role as an endogenous negative regulator of PKCmediated dense granule secretion and aggregation. Further, PKC has been reported to phosphorylate PLD2 [65] leading to the inactivation of the enzyme suggesting a feedback loop for PLD/PKC mediated activation and inactivation.
Former studies demonstrated that PLD1 inhibition/deficiency in platelets led to reduced integrin activation and thrombus formation while degranulation and aggregation was unaffected by the lack of PLD1 [28] . However, to discriminate between PLD1-and PLD2-mediated effects of FIPI on platelet activation we analyzed platelet secretion and aggregation in Pld1 -/-platelets. FIPI treatment of Pld1 -/-platelets led to enhanced ATP release and aggregation compared to Pld1 -/-platelets indicating that basal highly active PLD2 may account for the observed effects on aggregation and secretion in human and murine platelets. This hypothesis was further confirmed by measuring PLD activity that was significantly reduced in Pld1 -/-platelets pre-treated with FIPI. In a recent study it was already shown that basal PLD activity was comparable between wild-type and Pld1 -/-platelets. Thus, the authors suggested that basal PLD activity is derived from activity of the PLD2 isoform in platelets, a hypothesis, that is supported by the present study [28] . Upon platelet activation PLD activity was strongly reduced indicating that PLD1 is responsible for the bulk of inducible PLD activity in activated murine platelets [28] . Former studies suggested that PLD2 displays high basal activity and is only moderately activated by classical PLD1 activators such as According to our findings and in line with current knowledge, we propose that FIPI-induced inhibition of the basal highly active PLD2 is responsible for enhanced platelet activation pointing to a novel role for PLD2 as endogenous negative regulator of dense granule secretion and aggregation and thus for platelet activation.
In the last years, PLD has been shown to play a role in several tumor types. PLD1 and PLD2 expression and activity are up regulated in different types of cancer therefore the inhibition of PLD was discussed to be a promising tool in cancer therapy [43] . In addition, PLD also plays a role in the context of immune responses [43] suggesting that PLD may also be a target for the treatment of disease with inflammatory components. FIPI pharmacokinetics show promising results in terms of half-life and bioavailability in vivo that renders FIPI an attractive substance for metastasis studies in mice [34] . However, according to the current study it has to be critically evaluated if the inhibition of PLD might be a useful strategy for therapy because one might expect that in vivo application of FIPI may lead to increased risk of pathological thrombus formation. Further studies are required to examine in vivo application of FIPI in animal studies and to understand PLD mediated cellular function and regulation and their impact on disease.
Conclusions
5.1
The PLD inhibitor FIPI enhances dense granule secretion and aggregation of human platelets.
5.2 FIPI has no effect on cytosolic Ca 2+ activity but needs proper Rho kinase signaling to mediate FIPI-induced effects on platelet activation. 
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